Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses

Journal of Immunology

Volumn 187, Issue 9, 2011, Pages 4431-4439

  Kemmler, Charles B ^a   Clambey, Eric T ^a   Kedl, Ross M ^a   Slansky, Jill E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 7 RECEPTOR ALPHA; METHIONYLASPARAGINYLLYSYLTYROSYLALANYLTYROSYLHISTIDYLMETHIONYLLEUCINE; PEPTIDE VACCINE; SERYLPROLYLSERYLTYROSYLALANYLTYROSYLHISTIDYLGLUTAMINYLPHENYLALANINE; SERYLPROLYLSERYLTYROSYLVALYLTYROSYLHISTIDYLGLUTAMINYLPHENYLALANINE; THREONYLPROLYLHISTIDYLPROLYLALANYLARGINYLISOLEUCYLGLYCYLLEUCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AGING; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DOWN REGULATION; EX VIVO STUDY; GENE DELETION; GENETIC VARIABILITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

AGING; ANIMALS; ANTIGENIC VARIATION; CANCER VACCINES; CELLS, CULTURED; DOWN-REGULATION; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MOLONEY MURINE LEUKEMIA VIRUS; UP-REGULATION; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 80555133374     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101555     Document Type: Article

References (65)

1. Marrack, P., K. Rubtsova, J. Scott-Browne, and J. W. Kappler. 2008. T cell receptor specificity for major histocompatibility complex proteins. Curr. Opin. Immunol. 20: 203-207.
2. De Visser, K. E., T. N. Schumacher, and A. M. Kruisbeek. 2003. CD8+ T cell tolerance and cancer immunotherapy. J. Immunother. 26: 1-11. (Pubitemid 36056820)
3. Redmond, W. L., and L. A. Sherman. 2005. Peripheral tolerance of CD8 T lymphocytes. Immunity 22: 275-284. (Pubitemid 40387470)
4. McMahan, R. H., and J. E. Slansky. 2007. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin. Cancer Biol. 17: 317-329. (Pubitemid 47211967)
5. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13: 529-538.
6. McMahan, R. H., J. A. McWilliams, K. R. Jordan, S. W. Dow, D. B. Wilson, and J. E. Slansky. 2006. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J. Clin. Invest. 116: 2543-2551. (Pubitemid 44330153)
7. Jordan, K. R., R. H. McMahan, C. B. Kemmler, J. W. Kappler, and J. E. Slansky. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc. Natl. Acad. Sci. USA 107: 4652-4657.
8. de Visser, K. E., T. A. Cordaro, H. W. Kessels, F. H. Tirion, T. N. Schumacher, and A. M. Kruisbeek. 2001. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J. Immunol. 167: 3818-3828.
9. Overwijk,W.W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/ pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277-286. (Pubitemid 28357756)
10. Salazar, E., S. Zaremba, P. M. Arlen, K. Y. Tsang, and J. Schlom. 2000. Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int. J. Cancer 85: 829-838. (Pubitemid 30131474)
11. Dyall, R., W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolić-Zugić. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188: 1553-1561. (Pubitemid 28516100)
12. Lustgarten, J., A. L. Dominguez, and C. Pinilla. 2006. Identification of crossreactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope. J. Immunol. 176: 1796-1805. (Pubitemid 43134324)
13. Slifka, M. K., and J. L. Whitton. 2001. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat. Immunol. 2: 711-717. (Pubitemid 32747160)
14. Fahmy, T. M., J. G. Bieler, M. Edidin, and J. P. Schneck. 2001. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 14: 135-143. (Pubitemid 32206516)
15. Aichele, P., K. Brduscha-Riem, S. Oehen, B. Odermatt, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1997. Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6: 519-529. (Pubitemid 27239343)
16. DeLeo, A. B., H. Shiku, T. Takahashi, M. John, and L. J. Old. 1977. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med. 146: 720-734. (Pubitemid 8175981)
17. Huang, A. Y., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93: 9730-9735. (Pubitemid 26296677)
18. Schirmbeck, R., P. Riedl, M. Kupferschmitt, U. Wegenka, H. Hauser, J. Rice, A. Kröger, and J. Reimann. 2006. Priming protective CD8 T cell immunity by DNA vaccines encoding chimeric, stress protein-capturing tumor-associated antigen. J. Immunol. 177: 1534-1542. (Pubitemid 44092487)
19. McWilliams, J. A., R. T. Sullivan, K. R. Jordan, R. H. McMahan, C. B. Kemmler, M. McDuffie, and J. E. Slansky. 2008. Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine 26: 1863-1873.
20. Jordan, K. R., R. H. McMahan, J. Z. Oh, M. R. Pipeling, D. M. Pardoll, R. M. Kedl, J. W. Kappler, and J. E. Slansky. 2008. Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J. Immunol. 180: 188-197.
21. Jain, A., J. E. Slansky, L. C. Matey, H. E. Allen, D. M. Pardoll, and R. D. Schulick. 2003. Synergistic effect of a granulocyte-macrophage colonystimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann. Surg. Oncol. 10: 810-820. (Pubitemid 40486882)
22. McCubrey, J., and R. Risser. 1982. Genetic interactions in the spontaneous production of endogenous murine leukemia virus in low leukemic mouse strains. J. Exp. Med. 156: 337-349. (Pubitemid 12041398)
23. Pinter, A., W. J. Honnen, J. S. Tung, P. V. O'Donnell, and U. Hämmerling. 1982. Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies. Virology 116: 499-516. (Pubitemid 12163303)
24. Ozato, K., T. H. Hansen, and D. H. Sachs. 1980. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J. Immunol. 125: 2473-2477. (Pubitemid 11204138)
25. Evans, G. A., D. H. Margulies, B. Shykind, J. G. Seidman, and K. Ozato. 1982. Exon shuffling: mapping polymorphic determinants on hybrid mouse transplantation antigens. Nature 300: 755-757. (Pubitemid 13224354)
26. Wang, X. L., and J. D. Altman. 2003. Caveats in the design of MHC class I tetramer/antigen-specific T lymphocytes dissociation assays. J. Immunol. Methods 280: 25-35. (Pubitemid 37289213)
27. Savage, P. A., J. J. Boniface, and M. M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10: 485-492. (Pubitemid 29205484)
28. Haluszczak, C., A. D. Akue, S. E. Hamilton, L. D. Johnson, L. Pujanauski, L. Teodorovic, S. C. Jameson, and R. M. Kedl. 2009. The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion. J. Exp. Med. 206: 435-448.
29. Obar, J. J., K. M. Khanna, and L. Lefrançois. 2008. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 28: 859-869.
30. Moon, J. J., H. H. Chu, M. Pepper, S. J. McSorley, S. C. Jameson, R. M. Kedl, and M. K. Jenkins. 2007. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27: 203-213. (Pubitemid 47284919)
31. Truscott, S. M., L. Lybarger, J. M. Martinko, V. E. Mitaksov, D. M. Kranz, J. M. Connolly, D. H. Fremont, and T. H. Hansen. 2007. Disulfide bond engineering to trap peptides in the MHC class I binding groove. J. Immunol. 178: 6280-6289. (Pubitemid 46717411)
32. Wieckowski, S., P. Baumgaertner, P. Corthesy, V. Voelter, P. Romero, D. E. Speiser, and N. Rufer. 2009. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J. Immunol. 183: 5397-5406.
33. Aleksic, M., O. Dushek, H. Zhang, E. Shenderov, J. L. Chen, V. Cerundolo, D. Coombs, and P. A. van der Merwe. 2010. Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity 32: 163-174.
34. Kersh, G. J., E. N. Kersh, D. H. Fremont, and P. M. Allen. 1998. High- and lowpotency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 9: 817-826. (Pubitemid 29024461)
35. Hou, Y., B. Kavanagh, and L. Fong. 2008. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J. Immunol. 180: 1526-1534.
36. Aichele, P., K. Brduscha-Riem, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182: 261-266.
37. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93: 7855-7860. (Pubitemid 26277128)
38. Goldberg, M. V., C. H. Maris, E. L. Hipkiss, A. S. Flies, L. Zhen, R. M. Tuder, J. F. Grosso, T. J. Harris, D. Getnet, K. A. Whartenby, et al. 2007. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110: 186-192. (Pubitemid 47026834)
39. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687. (Pubitemid 43237609)
40. Parish, I. A., S. Rao, G. K. Smyth, T. Juelich, G. S. Denyer, G. M. Davey, A. Strasser, and W. R. Heath. 2009. The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood 113: 4575-4585.
41. Ginsberg, B. A., H. F. Gallardo, T. S. Rasalan, M. Adamow, Z. Mu, S. Tandon, B. B. Bewkes, R. A. Roman, P. B. Chapman, G. K. Schwartz, et al. 2010. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin. Cancer Res. 16: 4057-4065.
42. Dangoor, A., P. Lorigan, U. Keilholz, D. Schadendorf, A. Harris, C. Ottensmeier, J. Smyth, K. Hoffmann, R. Anderson, M. Cripps, et al. 2010. Clinical and immunological responses in metastatic melanoma patients vaccinated with a highdose poly-epitope vaccine. Cancer Immunol. Immunother. 59: 863-873.
43. Babatz, J., C. Röllig, B. Löbel, G. Folprecht, M. Haack, H. Günther, C. H. Köhne, G. Ehninger, M. Schmitz, and M. Bornhäuser. 2006. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol. Immunother. 55: 268-276. (Pubitemid 41682575)
44. Marshall, J. L., J. L. Gulley, P. M. Arlen, P. K. Beetham, K. Y. Tsang, R. Slack, J.W. Hodge, S. Doren, D.W. Grosenbach, J. Hwang, et al. 2005. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte- macrophage colony-stimulating factor, in patients with carcinoembryonic antigenexpressing carcinomas. J. Clin. Oncol. 23: 720-731. (Pubitemid 46224171)
45. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, S. L. Topalian, R. M. Sherry, N. P. Restifo, J. R. Wunderlich, C. A. Seipp, L. Rogers-Freezer, et al. 2003. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 9: 2973-2980. (Pubitemid 36993255)
46. Speiser, D. E., D. Liénard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A. M. Krieg, J. C. Cerottini, and P. Romero. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746. (Pubitemid 40322250)
47. Speiser, D. E., P. Baumgaertner, V. Voelter, E. Devevre, C. Barbey, N. Rufer, and P. Romero. 2008. Unmodified self antigen triggers human CD8 T cells withstronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA 105: 3849-3854. (Pubitemid 351723488)
48. Ayyoub, M., A. Zippelius, M. J. Pittet, D. Rimoldi, D. Valmori, J. C. Cerottini, P. Romero, F. Lejeune, D. Liénard, and D. E. Speiser. 2003. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin. Cancer Res. 9: 669-677. (Pubitemid 36182599)
49. Hoffmann, T. K., D. J. Loftus, K. Nakano, M. J. Maeurer, K. Chikamatsu, E. Appella, T. L. Whiteside, and A. B. DeLeo. 2002. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J. Immunol. 168: 1338-1347. (Pubitemid 34094504)
50. Hoffmann, T. K., A. D. Donnenberg, S. D. Finkelstein, V. S. Donnenberg, U. Friebe-Hoffmann, E. N. Myers, E. Appella, A. B. DeLeo, and T. L. Whiteside. Frequencies of tetramer+ T cells specific for the wild-type sequence p53 (264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res. 62: 3521-3529.
51. Tomita, M., T. Shimizu, M. Hara, T. Ayabe, and T. Onitsuka. 2009. Serum carcinoembryonic antigen level in non-small-cell lung cancer patients with preoperative normal serum level. Gen. Thorac. Cardiovasc. Surg. 57: 303-306.
52. Goodell, V., J. Waisman, L. G. Salazar, C. de la Rosa, J. Link, A. L. Coveler, J. S. Childs, P. A. Fintak, D. M. Higgins, and M. L. Disis. 2008. Level of HER-2/ neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol. Cancer Ther. 7: 449-454.
53. Saikali, S., T. Avril, B. Collet, A. Hamlat, J. Y. Bansard, B. Drenou, Y. Guegan, and V. Quillien. 2007. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J. Neurooncol. 81: 139-148. (Pubitemid 44963972)
54. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5: 677-685. (Pubitemid 29289432)
55. Echchakir, H., G. Dorotheé, I. Vergnon, J. Menez, S. Chouaib, and F. Mami- Chouaib. 2002. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc. Natl. Acad. Sci. USA 99: 9358-9363. (Pubitemid 34764618)
56. Tsushima, F., S. Yao, T. Shin, A. Flies, S. Flies, H. Xu, K. Tamada, D. M. Pardoll, and L. Chen. 2007. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110: 180-185. (Pubitemid 47026833)
57. Casares, N., L. Arribillaga, P. Sarobe, J. Dotor, A. Lopez-Diaz de Cerio, I. Melero, J. Prieto, F. Borrás-Cuesta, and J. J. Lasarte. 2003. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFNgamma- dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171: 5931-5939. (Pubitemid 37467211)
58. Casares, N., F. Rudilla, L. Arribillaga, D. Llopiz, J. I. Riezu-Boj, T. Lozano, J. López-Sagaseta, L. Guembe, P. Sarobe, J. Prieto, et al. 2010. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J. Immunol. 185: 5150-5159.
59. Golgher, D., E. Jones, F. Powrie, T. Elliott, and A. Gallimore. 2002. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32: 3267-3275. (Pubitemid 35414884)
60. Ercolini, A. M., B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J. P. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee. 2005. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602. (Pubitemid 40723662)
61. Nishioka, T., J. Shimizu, R. Iida, S. Yamazaki, and S. Sakaguchi. 2006. CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice. J. Immunol. 176: 6586-6593.
62. Sharma, S., A. L. Dominguez, and J. Lustgarten. 2006. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J. Immunol. 177: 8348-8355. (Pubitemid 44893796)
63. Grosso, J. F., M. V. Goldberg, D. Getnet, T. C. Bruno, H. R. Yen, K. J. Pyle, E. Hipkiss, D. A. Vignali, D. M. Pardoll, and C. G. Drake. 2009. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J. Immunol. 182: 6659-6669.
64. Jin, H. T., R. Ahmed, and T. Okazaki. 2011. Role of PD-1 in regulating T-cell immunity. Curr. Top. Microbiol. Immunol. 350: 17-37.
65. Mahnke, K., K. Schönfeld, S. Fondel, S. Ring, S. Karakhanova, K. Wiedemeyer, T. Bedke, T. S. Johnson, V. Storn, S. Schallenberg, and A. H. Enk. 2007. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120: 2723-2733. (Pubitemid 46651297)